AUTHOR=Jlassi Aida , Rejaibi Rim , Manai Maroua , Sahraoui Ghada , Guerfali Fatma Zahra , Charfi Lamia , Mezlini Amel , Manai Mohamed , Mrad Karima , Doghri Raoudha 

TITLE=VISTA/CTLA4/PD1 coexpression on tumor cells confers a favorable immune microenvironment and better prognosis in high-grade serous ovarian carcinoma

JOURNAL=Frontiers in Oncology

VOLUME=14

YEAR=2024

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1352053

DOI=10.3389/fonc.2024.1352053

ISSN=2234-943X

ABSTRACT=<sec><title>Introduction</title><p>Immunotherapy by blocking immune checkpoints programmed death/ligand (PD1/PDL1) and cytotoxic T-lymphocyte-associated protein 4(CTLA4) has emerged as new therapeutic targets in cancer. However, their efficacy has been limited due to resistance. A new- checkpoint V-domain Ig-containing suppressor of T cell activation (VISTA) has appeared, but the use of its inhibition effect in combination with antibodies targeting PDL1/PD1and CTLA4 has not been reported in ovarian cancer.</p></sec><sec><title>Methods</title><p>In this study, we investigated the expressions of VISTA, CTLA4, and PDL1 using immunohistochemistry (IHC)on 135 Formalin-Fixed Paraffin-Embedded (FFPE)tissue samples of High-grade serous carcinoma (HGSOC). VISTA, CTLA4, PDL1, PD1, CD8, CD4, and FOXP3 mRNA extracted from 429 patients with ovarian cancer in the Cancer Genome Atlas (TCGA) database was included as a validation cohort. Correlations between these checkpoints, tumor-infiltrating- lymphocytes (TILs), and survival were analyzed.</p></sec><sec><title>Results and discussion</title><p>CTLA4 was detectable in 87.3% of samples, VISTA in 64.7%, PD1 in 56.7%, and PDL1 in 48.1%. PDL1 was the only tested protein associated with an advanced stage (<italic>p</italic>=0.05). VISTA was associated with PDL1, PD1, and CTLA4 expressions (<italic>p</italic>=0.005, <italic>p</italic>=0.001, <italic>p</italic>=0.008, respectively), consistent with mRNA level analysis from the TCGA database. Univariate analyses showed only VISTA expression (<italic>p</italic>=0.04) correlated with overall survival (OS). Multivariate analyses showed that VISTA expression (<italic>p</italic>=0.01) and the coexpression of VISTA<sup>+</sup>/CTLA4<sup>+</sup>/PD1<sup>+</sup> (<italic>p</italic>=0.05) were associated with better OS independently of the clinicopathological features. Kaplan-Meier analysis showed that the coexpression of the VISTA<sup>+</sup>/CTLA4<sup>+</sup>/PDL1<sup>+</sup> and VISTA<sup>+</sup>/CTLA4<sup>+</sup>/PD1<sup>+</sup> checkpoints on tumor cells (TCs)were associated with OS (p=0.02 and <italic>p</italic>&lt;0.001; respectively). VISTA<sup>+</sup>/CTLA4<sup>+</sup>/PD1<sup>+</sup> in TCs and CD4<sup>+</sup>/CD8<sup>+</sup>TILswere associated with better 2-yer OS. This correlation may refer to the role of VISTA as a receptor in the TCs and not in the immune cells. Thus, targeting combination therapy blocking VISTA, CTLA4, and PD1 could be a novel and attractive strategy for HGSOC treatment, considering the ambivalent role of VISTA in the HGSOC tumor cells.</p></sec>